감염 관리 시장 : 제품 유형, 기술, 자동화 레벨, 재이용성, 휴대성, 대상 미생물, 용도, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The Infection Control Market is projected to grow by USD 84.14 billion at a CAGR of 6.68% by 2032.

Infection control is a core patient-safety, workforce-safety, and operational-resilience discipline across hospitals, ambulatory care, long-term care, laboratories, and community health settings. The industry spans hand hygiene, environmental cleaning, sterilization and disinfection, personal protective equipment, antimicrobial stewardship support, surveillance systems, and facility design practices that reduce pathogen transmission.

The need is measurable and persistent. The World Health Organization reports that, at any given time, healthcare-associated infections affect about 7 in 100 hospitalized patients in high-income countries and 15 in 100 in low- and middle-income countries. In the United States, the CDC has reported that roughly 1 in 31 hospital patients has at least one healthcare-associated infection on any given day. These data points keep infection prevention and control high on executive agendas because preventable infections increase mortality risk, length of stay, antimicrobial use, and avoidable costs.

Transformative Shifts in the Landscape

The infection control landscape is shifting from episodic compliance programs to continuous, risk-based prevention systems. Healthcare organizations are strengthening standard precautions, reprocessing controls, high-touch surface disinfection, water management, air quality monitoring, and antimicrobial stewardship as part of integrated quality programs rather than isolated departmental initiatives.

Several forces are accelerating change: rising antimicrobial resistance, aging populations, procedure growth in outpatient settings, and more stringent surveillance expectations from agencies such as the CDC, WHO, ECDC, and national health authorities. The COVID-19 pandemic also normalized higher expectations for respiratory hygiene, PPE readiness, ventilation, and outbreak preparedness, creating lasting demand for reliable infection control products, training, and analytics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical layer in infection prevention by improving surveillance sensitivity, accelerating outbreak detection, and helping teams prioritize interventions. AI-enabled models can analyze electronic health records, microbiology results, admission patterns, bed movement, device utilization, and environmental data to flag clusters earlier than manual review alone.

The cumulative impact is strongest when AI supports, rather than replaces, trained infection preventionists. Predictive analytics can identify patients at higher risk for surgical site infection, catheter-associated urinary tract infection, central line-associated bloodstream infection, or multidrug-resistant organism transmission. However, healthcare leaders must validate algorithms locally, monitor bias, protect patient data, and align AI outputs with evidence-based guidelines before using them in clinical governance.

Key Regional Insights

Asia-Pacific is experiencing rapid demand for infection control as large hospital networks expand, medical tourism grows, and governments invest in universal health coverage, with China, India, Japan, South Korea, and Australia setting different benchmarks for hospital quality and public health readiness. North America remains a mature, guideline-driven region shaped by CDC recommendations, CMS quality incentives, accreditation requirements, and strong adoption of surveillance, sterilization, and antimicrobial stewardship programs.

Latin America is advancing through public-private hospital investment and greater awareness of healthcare-associated infections, although uneven infrastructure and budget constraints affect consistency. Europe benefits from ECDC coordination, national surveillance networks, and robust medical device regulation. The Middle East is supported by large hospital infrastructure projects and healthcare transformation programs, especially in the Gulf. Africa presents high public health need, with infection prevention priorities tied to clean water, basic hygiene, laboratory capacity, vaccination, and workforce training.

Key Group Insights

ASEAN infection control priorities are shaped by fast-growing urban hospitals, expanding private healthcare, and cross-border medical travel, increasing the need for standardized sterilization, disinfection, and surveillance practices. GCC countries are investing in advanced hospitals, digital health infrastructure, and accreditation-led quality systems, making infection prevention a strategic part of national healthcare modernization.

The European Union benefits from harmonized regulatory frameworks, ECDC surveillance, and procurement standards that support quality and traceability. BRICS countries represent high-volume demand because of large patient populations, expanding healthcare access, and significant antimicrobial resistance concerns. G7 markets drive innovation, regulatory expectations, and premium adoption of validated technologies. NATO countries increasingly view infection control through health security, military medicine, pandemic preparedness, and resilient supply chain planning.

Key Country Insights

The United States leads in infection surveillance, accreditation-driven compliance, and adoption of digital quality tools, while Canada emphasizes publicly funded healthcare quality and national antimicrobial stewardship. Mexico and Brazil are expanding hospital capacity and private-sector quality systems, creating demand for standardized disinfection and sterilization. The United Kingdom, Germany, France, Italy, and Spain maintain mature infection prevention programs supported by national health systems, ECDC-aligned surveillance, and strict medical device oversight, while Russia continues to address hospital modernization and antimicrobial resistance management.

China and India represent large-scale demand for infection control products and training due to hospital expansion, high patient volumes, and increased focus on quality accreditation. Japan, Australia, and South Korea are advanced countries with strong technology adoption, aging populations, and established healthcare safety cultures. Across these countries, infection control purchasing is increasingly tied to evidence of efficacy, regulatory compliance, cost avoidance, and integration with hospital workflows.

Actionable Recommendations for Industry Leaders

Industry leaders should treat infection control as an enterprise risk-management function, not only a clinical compliance activity. The most effective strategies include strengthening hand hygiene programs, validating sterilization and high-level disinfection workflows, improving environmental services training, standardizing PPE protocols, and using surveillance data to target high-risk units and procedures.

Firms should invest in interoperable infection prevention platforms, antimicrobial stewardship analytics, supply chain redundancy, and workforce education. Vendors should differentiate through validated efficacy data, compatibility with clinical workflows, sustainability credentials, and transparent regulatory documentation. Healthcare providers should regularly benchmark HAI rates, audit adherence, and connect infection prevention outcomes to quality, reimbursement, and patient experience goals.

Research Methodology

This executive summary is built from secondary research and evidence-based interpretation of publicly available data from globally recognized authorities, including the WHO, CDC, ECDC, national health agencies, peer-reviewed antimicrobial resistance research, hospital quality frameworks, and medical device regulatory guidance. The analysis considers healthcare-associated infection burden, antimicrobial resistance trends, public health preparedness, and technology adoption patterns.

Insights were synthesized by comparing regional healthcare infrastructure, surveillance maturity, regulatory environments, procurement behavior, and digital transformation readiness. The methodology emphasizes verified sources, triangulated findings, and practical relevance for healthcare providers, infection control suppliers, technology vendors, investors, and policy stakeholders.

Conclusion

Infection control remains one of the most important levers for improving patient outcomes, protecting healthcare workers, reducing avoidable costs, and strengthening public health resilience. The burden of healthcare-associated infections and antimicrobial resistance demonstrates that prevention must remain continuous, measurable, and supported by leadership commitment.

Organizations that combine evidence-based protocols, trained infection prevention teams, reliable products, digital surveillance, and responsible AI will be best positioned to reduce transmission risks. As healthcare delivery becomes more distributed and data-driven, infection control will continue to evolve from a compliance requirement into a strategic performance advantage.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Infection Control Market, by Product Type

• 7.1. Air Purifiers
  • 7.1.1. HEPA Filters
  • 7.1.2. Ionizers
• 7.2. Disinfectants & Antiseptics
  • 7.2.1. Alcohol Based
  • 7.2.2. Chlorine Based
  • 7.2.3. Hydrogen Peroxide Based
• 7.3. Hand Hygiene Products
  • 7.3.1. Foam Sanitizers
  • 7.3.2. Gel Sanitizers
  • 7.3.3. Soap
  • 7.3.4. Wipes
• 7.4. Infection Monitoring Systems
• 7.5. Instrument Disinfectors
• 7.6. Sterilization Equipment
  • 7.6.1. Autoclaves
  • 7.6.2. EO Sterilizers
• 7.7. Surface Disinfectants

8. Infection Control Market, by Technology

• 8.1. AI & IoT
• 8.2. Chemical Sterilization
• 8.3. Filtration
• 8.4. Nanotechnology
• 8.5. Physical Sterilization
  • 8.5.1. Dry Heat
  • 8.5.2. Radiation
  • 8.5.3. Steam
• 8.6. Ultraviolet (UV) Disinfection

9. Infection Control Market, by Automation Level

• 9.1. Manual
• 9.2. Semi-Automated
• 9.3. Fully Automated

10. Infection Control Market, by Reusability

• 10.1. Single-Use
• 10.2. Reusable

11. Infection Control Market, by Portability

• 11.1. Portable
• 11.2. Benchtop
• 11.3. Fixed Installation

12. Infection Control Market, by Target Microorganism

• 12.1. Bacteria
• 12.2. Viruses
• 12.3. Fungi
• 12.4. Bacterial Spores
• 12.5. Mycobacteria

13. Infection Control Market, by Application

• 13.1. Biomedical Waste Management & Disposal
• 13.2. Disinfection & Sterilization
  • 13.2.1. Air Disinfection & HVAC Control
  • 13.2.2. Hand Hygiene & Antisepsis
  • 13.2.3. Medical Device Sterilization
  • 13.2.4. Surface Disinfection
  • 13.2.5. Surgical Instrument Disinfection
  • 13.2.6. Textile & Linen Disinfection
• 13.3. Infection Surveillance & Reporting Systems

14. Infection Control Market, by End User

• 14.1. Ambulatory Centers
• 14.2. Clinics
• 14.3. Food & Beverage Processing Firms
• 14.4. Hospitals
• 14.5. Pharmaceutical & Biotech Firms

15. Infection Control Market, by Distribution Channel

• 15.1. Offline
• 15.2. Online

16. Infection Control Market, by Region

• 16.1. Asia-Pacific
• 16.2. North America
• 16.3. Latin America
• 16.4. Europe
• 16.5. Middle East
• 16.6. Africa

17. Infection Control Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Infection Control Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025

20. Company Profiles

• 20.1. 3M Company
• 20.2. Abbott Laboratories
• 20.3. AliMed, Inc.
• 20.4. Amway Corporation
• 20.5. Ansell Ltd.
• 20.6. ASP International GmbH
• 20.7. Becton, Dickinson and Company
• 20.8. Belimed AG
• 20.9. bioMerieux SA
• 20.10. Cardinal Health Inc.
• 20.11. Colgate-Palmolive Company
• 20.12. Ecolab Inc.
• 20.13. Embuer Health Pvt. Ltd.
• 20.14. Essity AB
• 20.15. F. Hoffmann-La Roche Ltd.
• 20.16. Getinge AB
• 20.17. GOJO Industries, Inc.
• 20.18. Hartmann Group
• 20.19. Jiaxing Hongjie Commodity Co., Ltd.
• 20.20. Kao Corporation
• 20.21. Kimberly-Clark Corporation
• 20.22. Matachana Group
• 20.23. Medline Industries, LP
• 20.24. MELAG Medizintechnik GmbH & Co. KG
• 20.25. Merck KGaA
• 20.26. Metrex Research, LLC
• 20.27. Nice-Pak Products, Inc.
• 20.28. Pal International Ltd.
• 20.29. Procter & Gamble Company
• 20.30. Professional Disposables International, Inc.
• 20.31. Reckitt Benckiser Group PLC
• 20.32. Rockline Industries Ltd.
• 20.33. S. C. Johnson & Son, Inc.
• 20.34. Sotera Health LLC
• 20.35. Sterigenics International LLC
• 20.36. Steris Corporation
• 20.37. Unicharm Corporation
• 20.38. Unilever PLC
• 20.39. Weiman Products, LLC
• 20.40. Yessor Wipes